Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Labatec-Pharma S.A.
Street 1: 31, Rue du Cardinal-Journet
Street 2:
City: Geneve
Province:
Post Code: 1217
Country: Switzerland
Phone: 0041227859500
Organization Email: info@labatec.ch
Web Site: http://www.labatecpharma.com
Other Online Presence:

Focal Point Contact Information

Salutation: Mr.
First Name: Bassam
Last Name: Al Ariss
Title: Manager
Email: bassam.elariss@labatec.ch
Phone: 0041227859500

Alternate Focal Point Contact Information

Salutation: NA
First Name: NA
Last Name: NA
Title:  
Email: NA
Phone:  

General Information

Board Constituency: Private sector
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Private Sector
Organization Type - Secondary: None
Organization Description:
Labatec Pharma is a Swiss pharmaceuticals company based in Geneva backed by more than 50 years’ experience in proposing high-quality products.

Labatec The contribution of Labatec
Labatec: a reliable partner for treating Tuberculosis

With a strong portfolio of current and underdevelopment anti-tuberculosis drugs, we are committed to supply critical medication for this disease worldwide.

Currently Myambutol 100mg and 400mg (Ethambutol), Rifampicine 150mg and 300mg, are under assessment by the World Health Organisation for Prequalification. Most of our products are listed on the Global Fund Anti TB list of Pharmaceutical Suppliers.

Labatec provides Swiss Hospitals and Patients with:
•Isoniazid 100 mg & 300 mg

Labatec has a renewable import market authorisation from Swissmedic for Isoniazid 100mg (tablets). Isoniazid is registered and manufactured in the USA in FDA approved facilities. We currently have stock to cover the full needs of all Swiss hospitals and pharmacies. Starting in March 2012, Isoniazid has been integrated into the Reimbursement List of Specialties in Switzerland.
•Ethambutol 100 and 400 mg
•Rifampicine 150 and 300 mg
•Pyrazinamide 500 mg

The remaining three molecules are manufactured in our Geneva Switzerland facilities.
 
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Provision of drugs, diagnostics and commodities

Other Organization Information

Total number of staff in your organization: 26 - 50
Number of full-time staff who are directly involved with TB: 1 - 5
Number of part-time staff who are directly involved with TB: 0
Number of volunteers who are directly involved with TB: 0
 
How did you hear about the Stop TB Partnership: Involvement in TB control provision
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Involvement in Stop TB Working Groups
 
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
Labatec provides Swiss Hospitals and Patients with:
•Isoniazid 100 mg & 300 mg
 

Geographical Reach

Which country is your headquarters located in: Switzerland
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Afghanistan
Albania
Algeria
Andorra
Angola
Antigua and Barbuda
Argentina
Armenia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Cote d'Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Democratic People's Republic of Korea
Democratic Republic of the Congo
Democratic Republic of Timor-Leste
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Fiji
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
India
Indonesia
Iran (Islamic Republic of)
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Lithuania
Luxembourg
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mexico
Micronesia (Federated States of)
Monaco
Mongolia
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Qatar
Republic of Korea
Republic of Moldova
Republic of Montenegro
Republic of Serbia
Romania
Russian Federation
Rwanda
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Sweden
Switzerland
Syrian Arab Republic
Tajikistan
Thailand
The Former Yugoslav Rep of Macedonia
Togo
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom of Great Britain and Northern Ireland
United Republic of Tanzania
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Yemen
Zambia
Zimbabwe

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

TB Care Delivery:
work with MOH increasingly to educate on drug quality, high standard

Drug-Resistant TB:
development of MDR-TB drugs

New TB Drugs:
Develeopment of drug innovations

Declaration

Declaration of interests:
No conflicts of interest were delacred.

Application date: August 24, 2012
Last updated: May 14, 2018